ABSTRACT
INTRODUCTION
Activin is a member of the transforming growth factor-• (TGF- •E. Activins are multifunctional growth and differentiation factors participating in the regulation of many biological systems and processes including embryonic development, erythroid differentiation, and tumorigenesis (14, 17, 21, 22) by interactions with specific cell-surface receptors that show considerable subtype diversity (12) and have been identified in many tissues (10) , including the prostate (4, 20, 28) and prostate cancer cells (23). Activin A (the inhibin •A dimer) and activin B (the inhibin •B dimer) have profound effects on cell growth and function. Both stimulatory (8, 19, 30) and inhibitory (5, 27) effects have been documented depending on cell type. Follistatins are structurally unrelated proteins, which are glycosylated monomeric proteins derived from either of two mRNA splice variants coding for 288 or 315 amino acid proteins after removal of a common signal peptide at the time of synthesis), and bind activin, resulting in the neutralization of activin bioactivity (3, 11) .
Among the human prostate tumor cell lines LNCaP, DU145, and PC3, a strong growth-inhibitory effect in response to activin A is only seen after addition of exogenous activin A to the LNCaP cell line, which express functional activin receptors (2, 13, 24) . This growth inhibition is dose dependent, and importantly is androgen independent (13).
While activin was also found to inhibit proliferation of the DU145 cells to a lesser extent, no growth inhibition was seen in the PC3 cells (13) .
Prostate specific antigen (PSA) plays an important role in male reproductive physiology as well as it is very important as a tumor marker for prostate cancer. PSA is a serine protease and member of the tissue kallikrein family of proteases, and secreted into E-00443-2003.R1
seminal fluid at concentration of 0.5-3 mg/ml (i.e., about 1 million times those in plasma) (25) . In semen, PSA dissolves the gel forming after ejaculation by digesting semenogelin-1 and ---2 and fibronectin, causing release of the sperm, which is essential for sperm function (9) . Previous studies have shown that PSA is positively regulated by androgens via its receptor (16) . Activins were first identified by their ability to regulate pituitary follicle-stimulating hormone (FSH). Activins stimulate FSH-• gene expression and FSH secretion by the pituitary gonadotropes. By analogy with FSH, we hypothesized that activins regulates PSA in prostate cells. In the present study, using prostate cancer LNCaP cells, we show that activin A up-regulates PSA gene expression and secretion and that the effect is through androgen receptor (AR) independent pathway.
MATERIALS AND METHODS

Cell Culture
Human prostate cancer cell line LNCaP was obtained from American Type Culture Collection (ATCC, Rockville, MD) and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin at 
Cell Proliferation Assays
Cellular growth was assessed by total cell counts and by MTS assay. LNCaP cells were cultured with media with 10% FBS-DCC for 24 hours, and then media were changed into fresh media with 2% FBS-DCC with or without test agents. After 48-h treatment, cells were counted in a hemocytometer, and the viability of cells was determined by trypan blue dye exclusion. MTS assay was also performed using the CellTiter 96 Aqueous non-radioactive proliferation assay (Promega, Madison, WI) which is a colorimetric method for determining the number of viable cells in proliferation assays as reported previously (7).
For this assay, the MTS assay reagent was added to each well after 48-h treatment, and the absorbance was measured after 2-hour incubation at 37 o C using THERMOmax microplate reader (Molecular Devices, Sunnyvale, CA).
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Total RNA Extraction and cDNA Synthesis
Total RNA was extracted using the ISOGENE, following the manufacturer's instructions (Wako, Osaka, Japan). The concentration and purity of RNA were determined spectrophotometrically. Two micrograms of total RNA was reverse-transcribed into first strand cDNA using the ThermoScript TM RT system (Invitrogen Corp., Carlsbad, CA) at the final volume of 20 µl.
Quantitative Real-Time RT-PCR
Real-time monitoring of PCR reactions was performed using the LightCycler 
PSA Protein Assay
LNCaP cells were cultured with media with 10% FBS-DCC for 24 hours, and then media were changed into fresh media with 2% FBS-DCC with or without test agents. After 48-h treatment, the conditioned media were collected, centrifuged to remove residual cells, and stored at -20 o C. The Immulite third-generation PSA assay, which is a solid phase, 2-site sequential chemoluminescent enzyme immunoassay executed on the Immulite instrument (15, 26) , was used to measure PSA levels of culture medium. MTS assay was performed at the same time, and results were adjusted to PSA ng/ml by the cell number of the control group.
Hormones
Recombinant human follistatin and activin A were obtained from Wako, Osaka, Japan. Nonsteroidal antiandrogen bicalutamide was kindly provided by AstraZeneca Japan, Tokyo, Japan. 5•-dihydrotestosterone (DHT) was purchased from Sigma, St. Louis, MO.
Statistical Analysis
Statistical analysis was performed with JMP 5.0 software (SAS Institute, Cary, NC). Data are the mean plus or minus standard error of the mean (SEM) of triplicate or quadruplicate wells. Difference in data among treatment groups was analyzed by the one-way analysis of variance (ANOVA) followed by a multiple comparison Dunnett's test.
All P values of less than 0.05 were considered statistically significant. 
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RESULTS
The effect of Activin
The effect of activin A on PSA gene expression in LNCaP cells
The effects of activin A, DHT with or without their antagonists (follistatin or bicalutamide) on the expression of PSA mRNA in LNCaP cell cultures were examined by quantitative real-time RT-PCR. The time course study showed that 50 ng/ml Activin A up-regulated PSA gene expression after 4 hours and the effect reached maximal at 8 hours (data not shown). Figure 1A shows the PSA gene expression after increasing concentration of activin A for 8 hours. The effect of activin A to increase PSA mRNA levels was concentration-dependent. As shown in Figure 1B , DHT also up-regulated PSA gene expression, while follistatin or bicalutamide had no effects. Follistatin neutralized the effect of activin, whereas bicalutamide blocked the effect of DHT.
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The effect of activin A on PSA secretion by LNCaP cells
As shown in figure 2, activin A increased PSA secretion by LNCaP cells in a dose-dependent manner and in parallel with the change in mRNA levels described above.
Again the effect was blocked by follistatin, not by bicalutamide. Neither follistatin nor bicalutamide stimulated PSA secretion by LNCaP cells. DHT also increased PSA secretion, which was partially blocked by bicalutamide. Follistatin had no effects on the effect of DHT.
The interactions of activin A and DHT to up-regulate PSA production
The effects of activin A and DHT to increase PSA production were additive or synergistic in mRNA ( Figure 3A ) or protein levels ( Figure 3B ), respectively. In the present study, we show that activin A up-regulates PSA gene expression and increases PSA secretion by LNCaP cells. The effects of activin to increase PSA mRNA levels and PSA secretion were dose-dependent ( Figure 1A and 2), both of which were neutralized by follistatin ( Figure 1B and 2) . Previous studies have shown that the activin / follistatin system, which is present in the prostate tissue, plays a crucial role in the local regulation of human prostate cell growth. In addition, our results suggest that activin and follistatin also play an important role in the regulation of PSA production and secretion by the prostatic cells.
To our knowledge, only one previous study (31) addressed the effect of activin on PSA expression. The investigators of the study reported that activin stimulated the expression of prostatic acid phosphatase (PAP), PSA, and AR in LNCaP cells (31).
However, their experiments were not performed under androgen-depletion condition, which makes the results difficult to interpret. For example, we could consider that the result of activin to up-regulate PSA expression is due to the AR up-regulation. Our study is the first to demonstrate the up-regulation of PSA by activins in the absence of androgens. 
